Innovative Bispecific Nanobody Targeting CD40 and CLDN18 for Next-Generation Colon Cancer Therapy

VHH-P440 is a humanized bispecific nanobody construct designed to target both CD40 molecule (CD40) and claudin 18 (CLDN18). Currently at the Biological Testing stage, this program leverages the dual-targeting capacity of its modular structure for the potential treatment of colon cancer. By simultaneously engaging two distinct yet relevant molecular targets—CD40 molecule (CD40), important for immune modulation, and claudin 18 (CLDN18), associated with tumor cell specificity—VHH-P440 is strategically positioned to address key challenges in colon cancer therapy. Its advanced format and humanized design offer the promise of an innovative, next-generation therapeutic with enhanced selectivity and clinical potential.

Licensing Opportunity

VHH-P440 is available for licensing and open to strategic partnerships. We invite collaboration from pharmaceutical companies and research organizations interested in advancing this innovative bispecific nanobody program for colon cancer therapy.

Development Phase

Modality

VHH-P440 is a humanized bispecific fusion protein composed of two homodimeric polypeptides, each monomer integrating an antigen-binding fragment specific for claudin18.2 in tandem with the N-terminus of a human Fc fragment and a single-domain antibody directed against human CD40. The single-domain nanobody component confers small molecular size, superior tumor penetration, and excellent modularity, alongside high stability and solubility. Such structural attributes are especially advantageous for solid tumors like colon cancer, where deep tissue diffusion and sustained target engagement are critical. The inclusion of an Fc region enhances effector functions and prolongs half-life, collectively contributing to an innovative modality with versatile therapeutic application in disorders typified by complex tumor microenvironments.

Target

CD40 and CLDN18 are pivotal targets in immuno-oncology. CD40 is a member of the tumor necrosis factor receptor superfamily, broadly expressed on antigen-presenting cells including dendritic cells, B cells, and macrophages. Its activation modulates immune response, making CD40 a key target for immunotherapeutic strategies. CLDN18 is a tight junction protein, commonly overexpressed in certain gastrointestinal tumor subtypes and minimally present in most normal tissues, making CLDN18 an attractive tumor-specific marker. In colon cancer, dysregulated CD40 signaling may foster immunosuppressive microenvironments, while CLDN18 marks malignantly transformed epithelial cells. Targeting both CD40 and CLDN18 is strategically advantageous, enabling tumor-selective engagement and modulation of immune cell activation essential for effective colon cancer therapy. VHH-P440’s dual specificity for CD40 and CLDN18 establishes a unique competitive position in the therapeutic landscape, offering both direct tumor activity and immune system manipulation.

Mechanism of Action

VHH-P440 exerts its effect by concurrently binding to CLDN18 on tumor cells and CD40 on immune cells. The anti-CLDN18.2 domain provides target specificity to cancer cells expressing claudin18.2, promoting selective tumor localization. Simultaneously, the anti-CD40 domain modulates immune cell function by engaging CD40, a pivotal receptor in antigen-presenting cell activation, thus enhancing immune-mediated antitumor responses. This dual mechanism supports both direct tumor targeting and immune system potentiation. The nanobody-based format of VHH-P440 is amenable to further innovation, such as development into antibody–drug conjugates or expanded bispecific platforms, broadening its therapeutic applicability beyond colon cancer and supporting future pipeline diversification.

Colon Cancer

Colon cancer is among the most prevalent malignancies worldwide, significantly contributing to global cancer morbidity and mortality. Risk factors include age, genetic predisposition, lifestyle, and specific comorbidities. Standard-of-care therapies encompass surgical resection, chemotherapy, radiotherapy, and targeted biological agents; however, these approaches are frequently limited by resistance, toxicity, and lack of selectivity. Existing immunotherapies have demonstrated clear benefits in select patient groups, yet many individuals with advanced disease experience suboptimal outcomes, underscoring a critical need for new, differentiated strategies. VHH-P440 addresses these unmet needs by combining dual targeting of tumor and immune cells, which may enhance both selectivity and efficacy. Its innovative bispecific nanobody design represents a promising advance in overcoming current therapeutic limitations for colon cancer, with the potential to expand treatment options and improve patient outcomes.